Margaret M Centenera

List of Publications by Year in Descending Order

36 papers	1,582 citations	18 h-index	39 g-index
41 ext. papers	1,950 ext. citations	7.1 avg, IF	4.2 L-index

#	Paper	IF	Citations
36	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. *Nuclear Medicine and Biology*, **2021**, 93, 37-45	2.1	0
35	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. *Cancer Research*, **2021**, 81, 1704-1718	10.1	16
34	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 860-870	6.2	5
33	A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. *ELife*, **2021**, 10,	8.9	6
32	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. *Cancer Research*, **2021**, 81, 4981-4993	10.1	8
31	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. *ELife*, **2020**, 9,	8.9	31
30	Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. *Molecular Cancer Research*, **2020**, 18, 1500-1511	6.6	3
29	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). *BMJ Open*, **2020**, 10, e033667	3	5
28	Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry. *Scientific Reports*, **2019**, 9, 15008	4.9	10
27	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. *Molecular Cancer Research*, **2019**, 17, 949-962	6.6	41
26	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. *Molecular and Cellular Proteomics*, **2018**, 17, 1470-1486	7.6	19
25	Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. *Scientific Reports*, **2018**, 8, 2090	4.9	15
24	Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. *Prostate*, **2018** , 78, 308-317	4.2	28
23	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	17
22	A patient-derived explant (PDE) model of hormone-dependent cancer. *Molecular Oncology*, **2018**, 12, 1608-1622	7.9	54
21	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. *European Urology Oncology*, **2018**, 1, 325-337	6.7	23
20	The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 2689-2700	6.1	22

19	A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. *Prostate*, **2016**, 76, 1546-1559	4.2	18
18	IB□mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. *BMC Cancer*, **2016**, 16, 141	4.8	6
17	Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. *Endocrine-Related Cancer*, **2016**, 23, R219-27	5.7	54
16	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. *Endocrine-Related Cancer*, **2015**, 22, 805-18	5.7	18
15	Maximizing the Therapeutic Potential of HSP90 Inhibitors. *Molecular Cancer Research*, **2015**, 13, 1445-51	6.6	123
14	Hsp90: still a viable target in prostate cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2013**, 1835, 211-8	11.2	23
13	Ex vivo culture of human prostate tissue and drug development. *Nature Reviews Urology*, **2013**, 10, 483-7	5.5	96
12	Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. *Nature Communications*, **2013**, 4, 1923	17.4	106
11	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. *Oncotarget*, **2013**, 4, 691-704	3.3	43
10	Dual roles of PARP-1 promote cancer growth and progression. *Cancer Discovery*, **2012**, 2, 1134-49	24.4	260
9	Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. *Clinical Cancer Research*, **2012**, 18, 3562-70	12.9	85
8	GSTP1 DNA methylation and expression status is indicative of 5-aza-2¥deoxycytidine efficacy in human prostate cancer cells. *PLoS ONE*, **2011**, 6, e25634	3.7	41
7	Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. *Cancer Research*, **2009**, 69, 6131-40	10.1	277
6	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. *Expert Review of Clinical Pharmacology*, **2009**, 2, 619-30	3.8	4
5	Insights from AR Gene Mutations **2009**, 207-240		1
4	The contribution of different androgen receptor domains to receptor dimerization and signaling. *Molecular Endocrinology*, **2008**, 22, 2373-82		103
3	Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. *Molecular Endocrinology*, **2006**, 20, 1009-24		16
2	Androgens and the androgen receptor (AR)378-391		

1 Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition 2